Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

DNA polymerase kappa counteracts inflammation-induced mutagenesis in multiple organs of mice.

Hakura A, Sui H, Sonoda J, Matsuda T, Nohmi T.

Environ Mol Mutagen. 2019 May;60(4):320-330. doi: 10.1002/em.22272. Epub 2019 Jan 21.

PMID:
30620413
2.

Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study.

Kato M, Sugiyama KI, Fukushima T, Miura Y, Awogi T, Hikosaka S, Kawakami K, Nakajima M, Nakamura M, Sui H, Watanabe K, Hakura A.

Genes Environ. 2018 Apr 4;40:7. doi: 10.1186/s41021-018-0096-1. eCollection 2018.

3.

The strains recommended for use in the bacterial reverse mutation test (OECD guideline 471) can be certified as non-genetically modified organisms.

Sugiyama K, Yamada M, Awogi T, Hakura A.

Genes Environ. 2016 Jan 22;38:2. doi: 10.1186/s41021-016-0030-3. eCollection 2016.

4.

Wif1 and Ifitm3 gene expression preferentially altered in the colon mucosa of benzo[a]pyrene pre-treated mice following exposure to dextran sulfate sodium.

Koyama N, Hakura A, Toritsuka N, Sonoda J, Seki Y, Tohyama O, Asakura S, Nakano-Ito K, Hosokawa S.

Chem Biol Interact. 2015 Oct 5;240:164-70. doi: 10.1016/j.cbi.2015.07.012. Epub 2015 Aug 10.

PMID:
26271895
5.
6.

Rapid induction of colonic adenocarcinoma in mice exposed to benzo[a]pyrene and dextran sulfate sodium.

Hakura A, Seki Y, Sonoda J, Hosokawa S, Aoki T, Suganuma A, Kerns WD, Tsukidate K.

Food Chem Toxicol. 2011 Nov;49(11):2997-3001. doi: 10.1016/j.fct.2011.07.057. Epub 2011 Jul 30.

PMID:
21827817
7.

[Genotoxicity tests as a safety study required for the development of pharmaceuticals].

Hakura A.

Nihon Yakurigaku Zasshi. 2007 Jul;130(1):57-61. Review. Japanese. No abstract available.

PMID:
17634682
8.

Strategy for genotoxicity testing--metabolic considerations.

Ku WW, Bigger A, Brambilla G, Glatt H, Gocke E, Guzzie PJ, Hakura A, Honma M, Martus HJ, Obach RS, Roberts S; Strategy Expert Group, IWGT.

Mutat Res. 2007 Feb 3;627(1):59-77. Epub 2006 Dec 1.

PMID:
17141553
9.

Nitrogen-substitution effects on the mutagenicity and cytochrome P450 isoform-selectivity of chrysene analogs.

Yamada K, Hakura A, Kato TA, Mizutani T, Saeki K.

Mutat Res. 2005 Sep 5;586(1):87-95.

PMID:
16087391
10.

Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds.

Hakura A, Shimada H, Nakajima M, Sui H, Kitamoto S, Suzuki S, Satoh T.

Mutagenesis. 2005 May;20(3):217-28. Epub 2005 Apr 20.

PMID:
15843387
11.

Metabolic activation of 10-aza-substituted benzo[a]pyrene by cytochrome P450 1A2 in human liver microsomes.

Yamada K, Suzuki T, Hakura A, Mizutani T, Saeki K.

Mutat Res. 2004 Feb 14;557(2):159-65.

PMID:
14729370
12.

Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors.

Hakura A, Suzuki S, Sawada S, Sugihara T, Hori Y, Uchida K, Kerns WD, Sagami F, Motooka S, Satoh T.

Regul Toxicol Pharmacol. 2003 Feb;37(1):20-7.

PMID:
12662906
13.

Effect of 10-aza-substitution on benzo[a]pyrene mutagenicity in vivo and in vitro.

Yamada K, Suzuki T, Kohara A, Hayashi M, Hakura A, Mizutani T, Saeki K.

Mutat Res. 2002 Nov 26;521(1-2):187-200.

PMID:
12438015
14.

Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene.

Yoshioka N, Fuji S, Shimakage M, Kodama K, Hakura A, Yutsudo M, Inoue H, Nojima H.

Exp Cell Res. 2002 Sep 10;279(1):91-9.

PMID:
12213217
15.

An improvement of the Ames test using a modified human liver S9 preparation.

Hakura A, Suzuki S, Sawada S, Motooka S, Satoh T.

J Pharmacol Toxicol Methods. 2001 Nov-Dec;46(3):169-72.

PMID:
12183193
16.

Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer.

Li Q, Qi B, Oka K, Shimakage M, Yoshioka N, Inoue H, Hakura A, Kodama K, Stanbridge EJ, Yutsudo M.

Oncogene. 2001 Jul 5;20(30):3929-36.

17.

Comparison of the mutational spectra of the lacZ transgene in four organs of the MutaMouse treated with benzo[a]pyrene: target organ specificity.

Hakura A, Tsutsui Y, Sonoda J, Tsukidate K, Mikami T, Sagami F.

Mutat Res. 2000 Feb 14;447(2):239-47.

PMID:
10751607
18.

Assessment of potential mutagenic activities of a novel benzothiazole MAO-A inhibitor E2011 using Salmonella typhimurium YG1029.

Sato G, Asakura S, Hakura A, Tsutsui-Hiyoshi Y, Kobayashi N, Tsukidate K.

Mutat Res. 2000 Dec 20;472(1-2):163-9.

PMID:
11113709
19.
20.

Anti-mutagenic structural modification by fluorine-substitution in highly mutagenic 4-methylquinoline derivatives.

Kato T, Hakura A, Mizutani T, Saeki K.

Mutat Res. 2000 Feb 16;465(1-2):173-82.

PMID:
10708984
21.

[Mutagenicity study of gadobenate dimeglumine formulation (E7155) (1)--Reverse mutation assays in S. typhimurium and E. coli tester strains].

Hakura A, Sagami F, Tirone P, Morisetti A, Bussi S, Fassio F.

J Toxicol Sci. 1999 Nov;24 Suppl 1:89-94. Japanese.

PMID:
10637783
22.

Isolation of transformation suppressor genes by cDNA subtraction: lumican suppresses transformation induced by v-src and v-K-ras.

Yoshioka N, Inoue H, Nakanishi K, Oka K, Yutsudo M, Yamashita A, Hakura A, Nojima H.

J Virol. 2000 Jan;74(2):1008-13.

23.

Suppression of anchorage-independent growth of human cancer cell lines by the drs gene.

Yamashita A, Hakura A, Inoue H.

Oncogene. 1999 Aug 26;18(34):4777-87.

24.

Malignant transformation of human diploid fibroblasts and suppression of their anchorage independence by introduction of chromosome 13.

Oka K, Tomonaga Y, Nakazawa T, Ge HY, Bengtsson U, Stanbridge EJ, Yoshioka N, Li Q, Hakura A, Yutsudo M.

Genes Chromosomes Cancer. 1999 Sep;26(1):47-53.

PMID:
10441005
25.

Substituent effect of a fluorine atom on the mutagenicity of nitroquinolines.

Saeki K, Murakami R, Kohara A, Shimizu N, Kawai H, Kawazoe Y, Hakura A.

Mutat Res. 1999 May 17;441(2):205-13.

PMID:
10333534
26.

Multiple organ mutation in the lacZ transgenic mouse (Muta mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene.

Hakura A, Tsutsui Y, Sonoda J, Mikami T, Tsukidate K, Sagami F, Kerns WD.

Mutat Res. 1999 May 3;426(1):71-7.

PMID:
10320752
27.

Expression of latent and replicative-infection genes of Epstein-Barr virus in macrophage.

Shimakage M, Kimura M, Yanoma S, Ibe M, Yokota S, Tsujino G, Kozuka T, Dezawa T, Tamura S, Ohshima A, Yutsudo M, Hakura A.

Arch Virol. 1999;144(1):157-66.

PMID:
10076516
28.
29.

Reduction of syndecan-1 mRNA in cervical-carcinoma cells is involved with the 3' untranslated region.

Nakanishi K, Yoshioka N, Oka K, Hakura A.

Int J Cancer. 1999 Feb 9;80(4):527-32.

30.

Human papillomavirus-induced carcinogenesis with p53 deficiency in mouse: novel lymphomagenesis in HPV16E6E7 transgenic mice mimicking p53 defect.

Li Q, Yoshioka N, Yutsudo M, Inafuku S, Aozasa K, Kitamura Y, Aizawa S, Nishimune Y, Hakura A, Kondoh G.

Virology. 1998 Dec 5;252(1):28-33.

31.

Advantage of the use of human liver S9 in the Ames test.

Hakura A, Suzuki S, Satoh T.

Mutat Res. 1999 Jan 2;438(1):29-36.

PMID:
9858674
32.

Establishment of an epidermal growth factor-dependent, multipotent neural precursor cell line.

Nakagaito Y, Satoh M, Kuno H, Iwama T, Takeuchi M, Hakura A, Yoshida T.

In Vitro Cell Dev Biol Anim. 1998 Jul-Aug;34(7):585-92.

PMID:
9719419
33.

Toxicity profile of benzo[a]pyrene in the male LacZ transgenic mouse (MutaMouse) following oral administration for 5 consecutive days.

Hakura A, Sonoda J, Tsutsui Y, Mikami T, Imade T, Shimada M, Yaguchi S, Yamanaka M, Tomimatsu M, Tsukidate K.

Regul Toxicol Pharmacol. 1998 Jun;27(3):273-9.

PMID:
9693078
34.

Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse).

Hakura A, Tsutsui Y, Sonoda J, Kai J, Imade T, Shimada M, Sugihara Y, Mikami T.

Mutat Res. 1998 Feb 26;398(1-2):123-30.

PMID:
9626972
35.

Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.

Inoue T, Oka K, Yong-Il H, Vousden KH, Kyo S, Jing P, Hakura A, Yutsudo M.

Mol Carcinog. 1998 Mar;21(3):215-22.

PMID:
9537653
36.

Suppression of v-src transformation by the drs gene.

Inoue H, Pan J, Hakura A.

J Virol. 1998 Mar;72(3):2532-7.

38.

Detection of Epstein-Barr virus transcripts in anaplastic large-cell lymphomas by mRNA in situ hybridization.

Shimakage M, Nakamine H, Tamura S, Takenaka T, Yutsudo M, Hakura A.

Hum Pathol. 1997 Dec;28(12):1415-9.

PMID:
9416699
39.

Suppression of tumor growth by the 3' untranslated region of mel-18 in 3Y1 cells transformed by the E6 and E7 genes of human papillomavirus type 18.

Ishiwatari H, Nakanishi K, Kondoh G, Hayasaka N, Li Q, Yamashita A, Inoue H, Hakura A.

Cancer Lett. 1997 Jul 15;117(1):57-65.

PMID:
9233832
41.

Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways.

Matsumoto K, Shibata H, Fujisawa JI, Inoue H, Hakura A, Tsukahara T, Fujii M.

J Virol. 1997 Jun;71(6):4445-51.

42.

Mutagenicity of dihydroxybenzenes and dihydroxynaphthalenes for Ames Salmonella tester strains.

Hakura A, Tsutsui Y, Mochida H, Sugihara Y, Mikami T, Sagami F.

Mutat Res. 1996 Dec 20;371(3-4):293-9.

PMID:
9008731
43.

Increased sensitivity of EBNA2-transformed rat fibroblasts to ionizing radiation.

Shimakage M, Miyata Y, Inoue H, Yutsudo M, Hakura A.

Int J Cancer. 1996 Nov 27;68(5):612-5.

44.
46.

Isolation of a novel gene down-regulated by v-src.

Pan J, Nakanishi K, Yutsudo M, Inoue H, Li Q, Oka K, Yoshioka N, Hakura A.

FEBS Lett. 1996 Mar 25;383(1-2):21-5.

47.

Cloning of a new cytokine that induces IFN-gamma production by T cells.

Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al.

Nature. 1995 Nov 2;378(6552):88-91.

PMID:
7477296
48.

Tumorigenicity of EBNA2-transfected cells.

Shimakage M, Kurata A, Inoue H, Okamoto Y, Yutsudo M, Hakura A.

FEBS Lett. 1995 Sep 11;371(3):245-8.

49.

Mutagenicity of benzoquinones for Ames Salmonella tester strains.

Hakura A, Mochida H, Tsutsui Y, Yamatsu K.

Mutat Res. 1995 Jun;347(1):37-43.

PMID:
7596366

Supplemental Content

Loading ...
Support Center